MRESVIA | FDA - U.S. Food and Drug Administration
Dec 26, 2024 · Active immunization for the prevention of lower respiratory tract disease (LRTD) caused by respiratory syncytial virus (RSV) in individuals 60 years of age and older. Product …
mRESVIA® (Respiratory Syncytial Virus Vaccine) - Moderna
Online: Moderna's Adverse Event Intake Portal or U.S. HHS's Vaccine Adverse Event Reporting System. Connect with us. Email: [email protected] Call: 1-866-MODERNA (1-866 …
Moderna RSV Vaccine Summary | Vaccines & Immunizations
Jul 5, 2024 · mRESVIA is indicated for active immunization for the prevention of LRTD caused by RSV in individuals 60 years of age and older. When ordering vaccines directly from Moderna, …
Efficacy and Safety of an mRNA-Based RSV PreF Vaccine in Older …
Dec 13, 2023 · Respiratory syncytial virus (RSV) can cause substantial morbidity and mortality among older adults. An mRNA-based RSV vaccine, mRNA-1345, encoding the stabilized RSV …
Moderna Receives U.S. FDA Approval for RSV Vaccine mRESVIA(R)
May 31, 2024 · Moderna expects to have mRESVIA available for eligible populations in the U.S. by the 2024/2025 respiratory virus season. Moderna has filed for mRNA-1345 approval with …
Protect yourself against RSV with - Moderna
Protect yourself against RSV with mRESVIA by Moderna. mRESVIA is used to protect adults aged 60 or older against lower respiratory tract disease caused by respiratory syncytial virus …
FDA approves Moderna’s mRNA RSV vaccine for older adults
May 31, 2024 · The US Food and Drug Administration has approved another vaccine that can help protect older people from respiratory syncytial virus, known as RSV. The shot, made by …
Introducing the World’s First mRNA Vaccine Against RSV - Moderna
mRESVIA is Moderna’s mRNA vaccine approved in the U.S. to protect adults aged 60 years and over from severe lower respiratory tract disease (LRTD) caused by respiratory syncytial virus, …
Respiratory syncytial virus (RSV) can cause substantial morbidity and mortality among older adults. An mRNA-based RSV vaccine, mRNA-1345, encoding the stabilized RSV prefusion F …
ACIP Evidence to Recommendations for Use of Moderna RSV …
Sep 5, 2024 · Learn more about the ACIP Evidence to Recommendations for Use of Moderna RSV Vaccine (mResvia) in All Adults Aged ≥75 years and in Adults Aged 60–74 at Increased …